This FDA Breakthrough designated medical device is a digital biomarker for cognition and motor disorders. Through AI-aided analysis of personal device interactions, this device passively collects and analyzes data on HOW people interact with their personal devices from home. Pharma can use this device across a wide variety of diseases to develop meaningful digital endpoints for early detection, disease progression monitoring, and measuring the impact of therapeutic compounds to support pipeline development, decrease trial costs, and expedite time to market.
Richie Bavasso, CEO - email@example.com
Sri Mruthik, CTO - firstname.lastname@example.org